| Objective: Chronic prostatitis/ chronic pelvic pain syndrome(CP/CPPS) is a common condition in urological outpatients. The urinary, psychosocial, organ-specific, infection, neurological/systemic and tenderness(UPOINT) phenotype system has been validated to be an effective phenotype system in classifying patients with CP/CPPS in western populations. To validate the utility of the UPOINT system and evaluate the effect of multimodal therapy based on the UPOINT system, we performed this study.Methods: The outpatient patients with CP/CPPS were prospectively offered multimodal therapy using the UPOINT system on 6 domains and re-examined after 6 months. The patients’ symptom severity were evaluated by the National Institutes of Health-Chronic Prostatitis Symptoms Index(NIH-CPSI). Analysis the correlation between the number of positive domains and symptom severity.A minimum 6-point drop in NIH-CPSI was set to be the primary endpoint. Finally, 140 patients were enrolled in the study.Results: The percentage of patients with each domain was 59.3%, 45.0%, 49.3%, 22.1%, 37.9%, and 56.4% for the UPOINT, respectively. The number of positive domains significantly correlated with symptom severity, which is measured by total NIH-CPSI scores(r = 0.796, P < 0.001). Symptom duration was associated with a greater number of positive domains(r = 0.589, P < 0.001). With 6 months follow-up at least, 75.0%(105/140) had at least a 6-point improvement in NIH-CPSI after taking the therapy. All NIH-CPSI scores were significantly improved from original ones: pain 10.14 ± 4.26 to 6.60 ± 3.39, urinary 6.29 ± 2.42 to 3.63 ± 1.52, quality of life 6.56 ± 2.44 to 4.06 ± 1.98, and total 22.99 ± 7.28 to 14.29 ± 5.70(all P < 0.0001).Conclusions: The UPOINT clinical phenotyping system could direct the diagnose and treatment of CP/CPPS. Compared with monotherapy, The individual multimodal therapy can improve treatment effect and the patient’s quality of life. |
PDF Full Text Request